OLEAN-12-ENE-28-CARBOXY-3BETA-HEXADECANOATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WAESUNHGNAUFBW-SWSFNTIQSA-N
Smiles	CCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2CC=C4[C@@H]5CC(C)(C)CC[C@@]5(CC[C@@]34C)C(=O)O)C1(C)C
InChI	InChI=1S/C46H78O4/c1-9-10-11-12-13-14-15-16-17-18-19-20-21-22-39(47)50-38-26-27-43(6)36(42(38,4)5)25-28-45(8)37(43)24-23-34-35-33-41(2,3)29-31-46(35,40(48)49)32-30-44(34,45)7/h23,35-38H,9-22,24-33H2,1-8H3,(H,48,49)/t35-,36-,37+,38-,43-,44+,45+,46-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C46H78O4
Molecular Weight	695.11
AlogP	13.42
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	17.0
Polar Surface Area	63.6
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	50.0

Assay Description	Organism	Bioactivity
Antifeedant activity against fourth-instar larval stage of Spodoptera litura reared on castor leaves assessed as decrease in food consumption at 50 ug/cm2 after 48 hr by no-choice leaf disk assay relative to untreated control	Spodoptera litura	71.0 %
Antifeedant activity against fourth-instar larval stage of Spodoptera litura reared on castor leaves assessed as decrease in food consumption at 150 ug/cm2 after 48 hr by no-choice leaf disk assay relative to untreated control	Spodoptera litura	50.0 %
Antifeedant activity against fourth-instar larval stage of Spodoptera litura reared on castor leaves assessed as decrease in food consumption at 100 ug/cm2 after 48 hr by no-choice leaf disk assay relative to untreated control	Spodoptera litura	40.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2272673
PubChem	14138831

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).